Talvey (talquetamab-tgvs) is an FDA-approved treatment for relapsed or refractory multiple myeloma in adults who have already tried at least four prior lines of therapy.
It works by connecting myeloma cells and T cells (immune cells) together, activating the T cells to destroy the myeloma. It's given as an injection under Show Full Answer
Talvey (talquetamab-tgvs) is an FDA-approved treatment for relapsed or refractory multiple myeloma in adults who have already tried at least four prior lines of therapy.
It works by connecting myeloma cells and T cells (immune cells) together, activating the T cells to destroy the myeloma. It's given as an injection under the skin by a healthcare professional — not at home.
How it's given:
- Treatment starts with smaller "step-up" doses over the first few days
- After that, it's given either once a week or once every two weeks
- Hospital monitoring for 48 hours is required after each step-up dose
How well does it work?
- About 73% of people responded to Talvey
- Around 33–35% had a complete response
- It typically started working within about 1.2–1.3 months Common side effects include:
- Taste changes and dry mouth
- Skin problems, rash, and very dry skin
- Nail problems
- Fatigue and weight loss
- Fever
- Trouble swallowing
Serious side effects to watch for:
- Cytokine release syndrome (CRS) — fever, chills, low blood pressure, trouble breathing
- Neurologic problems — confusion, trouble speaking, seizures
- Serious infections
- Low blood cell counts
- Liver problems
MyMyelomaTeam members who've used Talvey suggest preparing for taste changes early, using products like Biotene for dry mouth and CeraVe for dry skin, and staying in close contact with your care team throughout treatment.
Always talk with your doctor about whether Talvey is right for your situation, and report any side effects promptly.
AI-generated responses are not a substitute for medical advice. These services are not intended to
diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.
October 1